Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
for Amyloidosis
39 locations incl. La Jolla
Sponsor: Eidos Therapeutics, a BridgeBio company
Sex: All·Age: 18 - 75
Code: NCT06563895·Phase 3·Recruiting·Listed Aug 2024